216 related articles for article (PubMed ID: 15492788)
21. Establishment of new multidrug-resistant human osteosarcoma cell lines.
Oda Y; Matsumoto Y; Harimaya K; Iwamoto Y; Tsuneyoshi M
Oncol Rep; 2000; 7(4):859-66. PubMed ID: 10854558
[TBL] [Abstract][Full Text] [Related]
22. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
23. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
24. Multimodal transfer of MDR by exosomes in human osteosarcoma.
Torreggiani E; Roncuzzi L; Perut F; Zini N; Baldini N
Int J Oncol; 2016 Jul; 49(1):189-96. PubMed ID: 27176642
[TBL] [Abstract][Full Text] [Related]
25. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
26. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
27. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
[TBL] [Abstract][Full Text] [Related]
28. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Takeshita H; Gebhardt MC; Springfield DS; Kusuzaki K; Mankin HJ
J Bone Joint Surg Am; 1996 Mar; 78(3):366-75. PubMed ID: 8613443
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
30. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
31. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
32. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].
Zhu KP; Zhang CL
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):250-255. PubMed ID: 28550663
[No Abstract] [Full Text] [Related]
33. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
35. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
36. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
Minami H; Ohtsu T; Fujii H; Igarashi T; Itoh K; Uchiyama-Kokubu N; Aizawa T; Watanabe T; Uda Y; Tanigawara Y; Sasaki Y
Jpn J Cancer Res; 2001 Feb; 92(2):220-30. PubMed ID: 11223552
[TBL] [Abstract][Full Text] [Related]
38. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
39. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
40. Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
Cancer Lett; 1998 Apr; 126(1):75-81. PubMed ID: 9563651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
